drugset
drugset / Trial / NCT01548911

Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia

NCT01548911 ↗

Phase 2 Withdrawn Wake Forest University Health Sciences National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This clinical trial studies the side effects of gemtuzumab ozogamicin and how well it works in treating patients with acute myeloid leukemia. Monoclonal antibodies, such as gemtuzumab ozogamicin, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them

Timeline

Start
2012-05
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemtuzumab Ozogamicin Monoclonal antibody — Intravenous

Indications

acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, inv(16)(p13.1;q22) acute promyelocytic leukemia